Business Wire

FLEXJET

2.12.2020 10:34:40 CET | Business Wire | Press release

Share
Flexjet Advances European Expansion with Delivery of First Embraer Praetor 600

Flexjet Ltd. , offering travelers access to the world’s most luxurious fleet of private jets, accepted delivery of the first Praetor 600 aircraft in its European-based fleet, marking a significant milestone in the expansion of the company’s global business. Flexjet is the only shared-ownership/fractional provider of the Praetor 600 , part of a US$1.4 billion order for Embraer Executive Jets, a division of Embraer S.A. (NYSE: ERJ; BM&FBOVESPA: EMBR3), that was announced in October 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005564/en/

European Managing Director Marine Eugène leads the team headquartered at Flexjet House in the Mayfair neighbourhood in the west end of London. In addition, Flexjet has opened facilities including a European Tactical Control Centre in the United Kingdom to coordinate flight logistics, an aircraft maintenance facility in Milan and Flexjet House, where an experience center envelops current and prospective Flexjet shared aircraft Owners.

“Flexjet has taken the time to lay the groundwork to properly serve those entering the shared aircraft ownership market in Europe,” said Eugène. “Now that we have the infrastructure in place, we are growing our fleet with the addition of our new Praetor 600 aircraft. The Praetor 600 will form part of our Red Label by Flexjet offering, bringing to European-based travelers a unique combination of innovative technology, luxury and premium service. Our objective is to give Owners the ability to travel not just in North America but throughout Europe, Africa and the Middle East without leaving the safety and security of the Flexjet family.”

Currently, only 110 shared-ownership aircraft are providing more than 800,000 flight hours per year in Europe. In contrast, there are nearly 700 private aircraft supporting 1.2 million flight hours annually in the U.S. With its growing presence in Europe, Flexjet intends to meet the needs of a European market, underserved by existing flight providers, offering the personalized levels of service, consistency and attention to detail for which Flexjet is known.

The Praetor 600 will be part of the premium Red Label by Flexjet programme . The only offering of its kind, Red Label by Flexjet features flight crews assigned to a single, specific aircraft, custom cabin interiors and the youngest fleet in the industry as well as innovations established in response to the COVID-19 pandemic.

Having the youngest fleet in the industry is just one of the ways that Flexjet is meeting the industrywide commitment to achieving its sustainability goals by 2050. To meet that target, Flexjet Ltd. has implemented a standard sustainability offering that goes far beyond carbon-neutral. All Owners’ flights will be fully emissions-neutral, compensating for carbon dioxide (CO2) emissions and also other non-carbon dioxide warming pollutants in aviation, such as water vapor, aerosol sulphate and nitrous oxides. This comprehensive programme requires offsetting an additional 300 percent on top of standard CO2 emissions, a truly innovative first in the sector.

As the fleet launch customer for the Praetor 600, Flexjet will add it to its existing European-based fleet of Embraer Legacy 500s and 600s. Announced by Embraer in 2018, the super-midsize Praetor 600 seats nine passengers plus a cabin server and offers class-leading capabilities that make it ideal for both business and leisure use. Its exceptional short-field performance enables it to fly into small airports – including London City (EGLC) – which reduces transit time both to businesses in city centers and to remote vacation locations. The Praetor 600 is the farthest-flying super-midsize jet in the world and has a range of more than 4,000 miles, making it easy to fly without stops from Paris to New York or London to Dubai.

In addition, the Praetor 600 is equipped with unparalleled high-speed satellite Wi-Fi connectivity and an industry-first touchscreen Upper Tech Panel that puts flight information and cabin controls at the passenger’s fingertips. In the cockpit, the Praetor 600 is the first super-midsize jet with full fly-by-wire technology, which powers the Active Turbulence Reduction that not only makes every flight the smoothest but also the most efficient possible. One of the distinctive features of the Praetor 600 is the enlarged winglets, roughly six feet high, which contribute to the aircraft’s fuel efficiency.

The aircraft air quality management system is comprehensive, with the ability to move 100 percent fresh air through the cabin and an additional HEPA filter that further improves air quality by filtering out 99.97 percent of all particles including bacteria, viruses and fungi. The Praetor 600 also has a cabin altitude of 5,800 feet when the aircraft is cruising at 45,000 feet. This pressure level, combined with higher humidity levels, means travellers will feel less fatigued and more active during the flight and better refreshed on arrival.

“With private jet service recovering much faster than commercial aviation in the wake of the COVID-19 pandemic, it’s clear that travelers want to minimize their risk of exposure to the coronavirus, and private jets are a lower-risk way to fly in the COVID-19 era. That makes this the perfect time to bring both the versatile Praetor 600 and the Red Label experience to the European market,” said Flexjet Chief Executive Officer Michael Silvestro. “With Marine Eugène at the helm, we look forward to the continued growth and evolution of our European offering.”

Michael Amalfitano, President & CEO, Embraer Executive Jets , added “Flexjet is the fleet launch customer for the Praetor aircraft, continuing a two-decade-long partnership with Embraer. We are pleased that Flexjet is introducing the world’s most technologically advanced super-midsized aircraft, the Praetor 600, to the European shared ownership market and has the capabilities to thoroughly disrupt the business aviation market. We are confident that Flexjet passengers here in Europe will enjoy the ultimate experience in business and private aviation.”

Flexjet continues to be a leader in safety and the well-being of its Owners. Flexjet was the first private jet provider to decontaminate its cabins with anti-microbial treatments (MicroShield 360 in U.S.-based aircraft and Bacoban ® on EU-based aircraft). Each Flexjet cabin also is equipped with MedAire’s Universal Precaution Kit containing tools to help protect both passengers and crew from possible exposure. Every Flexjet pilot or crewmember wears masks and receives a mandatory temperature check pre-tour and a second while on duty. In addition, each crewmember remains in compliance with WHO-recommended guidelines for social distancing both on the ground and in the air.

About Flexjet

Flexjet first entered the fractional jet ownership market in 1995. Flexjet offers fractional jet ownership and leasing. Flexjet’s fractional aircraft programme is the first in the world to be recognized as achieving the Air Charter Safety Foundation’s Industry Audit Standard, is the first and only company to be honored with 21 FAA Diamond Awards for Excellence, upholds an ARG/US Platinum Safety Rating and is IS-BAO compliant at Level 2. Flexjet’s fractional programme fields an exclusive array of business aircraft—some of the youngest in the fractional jet industry, with an average age of approximately six years. In 2015, Flexjet introduced Red Label by Flexjet, which features the youngest fleet in the industry, flight crews dedicated to a single aircraft and the LXi Cabin Collection of interiors. To date there are more than 40 different interior designs across its fleet, which includes the Embraer Phenom 300, Legacy 450 and Praetor 500, Bombardier Challenger 350, the Gulfstream G450, G500, G650 and G700, and the Aerion AS2 supersonic business jets. Flexjet’s European fleet includes the Embraer Praetor 600, Legacy 500 and 600. Flexjet is a member of the Directional Aviation family of companies. For more details on innovative programmes and flexible offerings, visit www.flexjet.com or follow us on Twitter @Flexjet and on Instagram @FlexjetLLC .

Link:

ClickThru

Social Media:

https://www.facebook.com/Flexjet

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye